“Most clinicians who treat CLL know that ALC-only progression is less concerning for patient prognosis,” explained Dr. Lewis Wu, a fellow in the Hematology-Oncology program at Fred Hutch and first author of the study. But this distinction can be lost in clinical trials, where different forms of disease progression are often counted equally when evaluating the effectiveness of new therapies.
One of the most common measures of success in cancer clinical trials is progression-free survival (PFS), which measures how long patients live without their cancer worsening. In many phase 3 clinical trials, a treatment that extends PFS is considered more effective, regardless of the type of progression involved.
But for a disease like CLL, where some forms of progression are far more concerning than others, this raises an important question. Does a longer progression-free survival always translate into a meaningful benefit for patients?
Newer targeted therapies, including BTK inhibitors and BCL2 inhibitors, have demonstrated improvements in PFS compared to traditional chemoimmunotherapy in clinical trials, helping establish them as standard treatments for CLL. But when relatively mild changes like ALC-only progression are counted alongside more serious forms of disease progression, these comparisons may overlook important differences in how patients actually fare.
Dr. Gopal added, “Nobody’s really shown how this relates to clinical trials and whether we are measuring the outcomes that are actually most relevant to patients.”
Although PFS remains an important measure of treatment effectiveness, understanding what happens to patients after different forms of progression could provide a more complete picture of the benefits of newer therapies.
With this in mind, the researchers examined the medical records of 339 patients treated at the University of Washington/Fred Hutchinson Cancer Center. Patients had received one of three common treatment approaches: traditional chemoimmunotherapy, continuous BTK inhibitors, or fixed-duration BCL2 inhibitor-based therapy. The team compared the types of disease progression patients experienced and what happened afterward, including how long they survived and how much time passed before they required another treatment.
Their findings revealed a clear distinction. Patients who experienced ALC-only progression had significantly better outcomes than those whose disease progressed in other ways. Five years after progression, 83% of patients with ALC-only progression were still alive, compared to 56% of those with other forms of progression. Patients with ALC-only progression also had substantially longer treatment-free survival following progression, with a median of 14 months compared to just 2.2 months.
While previous research had linked ALC-only progression to better outcomes following chemoimmunotherapy, this study extended those findings to patients receiving newer targeted therapies.
The researchers also identified another important difference. Patients receiving chemoimmunotherapy were more likely to experience ALC-only progression than those receiving newer targeted therapies. Because ALC-only progression is associated with better outcomes, counting all types of progression equally could overestimate the benefit associated with newer therapies.
That doesn’t necessarily mean chemoimmunotherapy is better than the newer targeted therapies. Rather, the findings suggest that PFS alone may not capture the whole story when comparing treatments, particularly when considering the different demands they place on patients. Some newer therapies, such as continuous BTK inhibitors, require patients to take medication for years, with ongoing monitoring, potential accumulating side effects, and substantial costs. Understanding whether improvements in PFS translate into meaningful benefits for patients could help clinicians better weigh these trade-offs when choosing a treatment.
To provide a more complete picture of treatment effectiveness, the researchers suggest that future clinical trials report ALC-only progression separately from other forms of progression, or calculate PFS both with and without ALC-only progression events. Similar approaches are already used in prostate cancer research, where changes in disease-related biomarkers are distinguished from more clinically significant forms of progression.
“Moving forward, the field should consider revising either the trial endpoint or how it's reported to take into account that these different types of progression are not all equal,” said Dr. Wu.
More broadly, the study raises an important question about how cancer treatments are evaluated and whether clinical trials are measuring the outcomes that matter most to patients. Dr. Gopal added, “We have the privilege to take care of patients and it’s important to make sure we’re asking patient-relevant questions.” For someone living with CLL, the most meaningful measure of treatment success may not simply be how long their cancer takes to show signs of progression, but what those changes mean for their health, their treatment options, and their everyday lives.